Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
Greenland Mines Authorizes $20 Million Share Repurchase Program and Announces Capital Allocation Priorities
Greenland Mines' board authorized a $20 million share repurchase program via open-market purchases and 10b5-1 plans, with no obligation to buy any particular amount.
The authorization follows a recent raise of more than $59 million, which management says funds Sarfartoq and Skaergaard work through 2027 milestones while preserving buyback flexibility.
The authorization is discretionary and can be suspended at any time; capital priorities remain drilling, technical studies, permitting, and strategic partnerships.